We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

40 hedge funds and large institutions have $202M invested in Calidi Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

48% more funds holding

Funds holding: 27 → 40 (+13)

23% more capital invested

Capital invested by funds: $165M → $202M (+$37.7M)

0.01% more ownership

Funds ownership: 0.04% → 0.05% (+0.01%)

Holders
40
Holders Change
+13
Holders Change %
+48.15%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
8
Reduced
4
Closed
–
Calls
$599K
Puts
–
Net Calls
+$599K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$9.85M
2
SCM
Shaolin Capital Management
Florida
+$9.81M
3
AC
Aristeia Capital
Connecticut
+$9.75M
4
Millennium Management
Millennium Management
New York
+$4.88M
5
Nomura Holdings
Nomura Holdings
Japan
+$1.83M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$10.1M
2
AMH
Apollo Management Holdings
New York
-$435K
3
UBS Group
UBS Group
Switzerland
-$56.7K
4
AA
AQR Arbitrage
Connecticut
-$18.9K

CLDI Hedge Fund Activity: Q1 2022 in Review

40 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2022, worth a combined $202M — up 23% from $165M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CLDI positions and 0 closed out — a net gain of 13 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $9.85M. The largest seller was Highbridge Capital Management, cutting an estimated $10.1M.

  • 40 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2022, up from 27 in Q4 2021.
  • Funds reported $202M of Calidi Biotherapeutics stock for Q1 2022, up 23% quarter-over-quarter.
  • 13 funds opened new Calidi Biotherapeutics positions in Q1 2022 and 0 closed out, a net change of +13 holders.
  • The largest Calidi Biotherapeutics buyer in Q1 2022 was 683 Capital Management, an estimated $9.85M added.
  • The largest Calidi Biotherapeutics seller in Q1 2022 was Highbridge Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2022.